OncoMed Pharmaceuticals, Inc. (OMED) was a big mover last session, as its shares rose over 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the downtrend for the company, as the stock is now down almost 13% in the past one-month timeframe.
In the last 30 days, the company witnessed three negative estimate revisions and the Zacks Consensus Estimate also moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if Friday’s move higher lasts.
OncoMed Pharmaceuticals currently has a Zacks Rank #5 (Strong Sell) while its Earnings ESP is negative.
Other better-ranked stocks in the biomedical/gene industry include Gilead Sciences Inc. (GILD), Cambrex Corporation. (CBM) and China Biologic Products, Inc. (CBPO). All three sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment